Zentalis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ZNTL and other ETFs, options, and stocks.About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
CEOJulia Marie Eastland
CEOJulia Marie Eastland
Employees166
Employees166
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2014
Founded2014
Employees166
Employees166
ZNTL Key Statistics
Market cap213.86M
Market cap213.86M
Price-Earnings ratio-1.42
Price-Earnings ratio-1.42
Dividend yield—
Dividend yield—
Average volume4.55M
Average volume4.55M
High today$3.25
High today$3.25
Low today$2.90
Low today$2.90
Open price$3.16
Open price$3.16
Volume1.20M
Volume1.20M
52 Week high$3.95
52 Week high$3.95
52 Week low$1.01
52 Week low$1.01
Stock Snapshot
With a market cap of 213.86M, Zentalis Pharmaceuticals(ZNTL) trades at $2.91. The stock has a price-to-earnings ratio of -1.42.
On 2026-01-18, Zentalis Pharmaceuticals(ZNTL) stock traded between a low of $2.90 and a high of $3.25. Shares are currently priced at $2.91, which is +0.2% above the low and -10.6% below the high.
Zentalis Pharmaceuticals(ZNTL) shares are trading with a volume of 1.2M, against a daily average of 4.55M.
In the last year, Zentalis Pharmaceuticals(ZNTL) shares hit a 52-week high of $3.95 and a 52-week low of $1.01.
In the last year, Zentalis Pharmaceuticals(ZNTL) shares hit a 52-week high of $3.95 and a 52-week low of $1.01.
Analyst ratings
50%
of 8 ratingsBuy
50%
Hold
50%
Sell
0%
People also own
Based on the portfolios of people who own ZNTL. This list is generated using Robinhood data, and it’s not a recommendation.